Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19578179 | 1.00 | KCNN4 (0.41) | KCNN4ALDH1A1RIPK1PDK1PDK2 | |
| SCHEMBL12281394 | 0.84 | KCNN4 (0.42) | KCNN4ALDH1A1RIPK1PDK1PDK2 | |
| SCHEMBL12175054 | 0.83 | CYP2C19 (0.38) | KCNN4ALDH1A1RIPK1PDK1PDK2 | |
| SCHEMBL8920357 | 0.83 | CYP2C19 (0.38) | KCNN4ALDH1A1RIPK1PDK1PDK2 | |
| SCHEMBL10077236 | 0.79 | KCNN4 (0.44) | KCNN4ALDH1A1RIPK1PDK1PDK2 | |
| SCHEMBL1822203 | 0.79 | KCNN4 (0.49) | KCNN4ALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL8906107 | 0.78 | KCNN4 (0.43) | KCNN4ALDH1A1RIPK1PDK1PDK2 | |
| SCHEMBL31612947 | 0.75 | NPSR1 (0.44) | KCNN4RIPK1PDK1PDK2PDK3 | |
| SCHEMBL8915396 | 0.75 | KCNN4 (0.41) | KCNN4RIPK1PDK1PDK2PDK3 | |
| SCHEMBL19578315 | 0.75 | KCNN4 (0.41) | KCNN4RIPK1PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, MAVS | KCNN4 4457/4885ALDH1A1 241/4885RIPK1 2074/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNN4 4880/4885ALDH1A1 1144/4885RIPK1 3139/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | KCNN4 4880/4885ALDH1A1 1144/4885RIPK1 3139/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | KCNN4 4776/4885ALDH1A1 287/4885RIPK1 3538/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | KCNN4 4536/4885ALDH1A1 132/4885RIPK1 4155/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | KCNN4 4776/4885ALDH1A1 287/4885RIPK1 3538/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | KCNN4 4880/4885ALDH1A1 1144/4885RIPK1 3139/4885 |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNN4 4832/4885ALDH1A1 365/4885RIPK1 3705/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNN4 4880/4885ALDH1A1 1144/4885RIPK1 3139/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | KCNN4 4536/4885ALDH1A1 132/4885RIPK1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.